Analytical Data
-
基因名
MDC/CCL22
- Application
-
别名
CCL22; ABCD1; DC/B-CK; SCYA22; STCP1; Chemokine C-C-Motif Ligand 22; Small Inducible Cytokine Subfamily A(Cys-Cys)Member 22; Stimulated T-Cell Chemotactic Protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O00626
-
表达区间
Gly25~Gln93
-
蛋白长度
Partial
-
分子量
38kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MDC (CCL22) is a chemokine primarily involved in immune system regulation, particularly in the attraction and activation of immune cells such as T cells and dendritic cells. It plays a crucial role in the immune response by guiding these cells to sites of inflammation and promoting the development of specific immune responses. Research has shown that MDC/CCL22 is associated with various pathological conditions, including cancer, autoimmune diseases, and infectious diseases, where its expression may indicate disease progression or therapeutic outcomes. Studies have also highlighted the potential of MDC/CCL22 as a biomarker for diagnosing and monitoring these conditions. Furthermore, given its pivotal role in the immune system, MDC/CCL22 has garnered interest as a target for novel therapeutic interventions, including immunotherapies and vaccines. Understanding the structure and function of recombinant MDC/CCL22 protein is essential for developing these therapeutics, as it could enhance our ability to manipulate immune responses effectively. The production of recombinant MDC/CCL22 allows for detailed studies of its biological functions and interactions with receptors, providing insights that may lead to innovative treatment strategies for diseases characterized by dysregulated immune responses. As such, the exploration of recombinant MDC/CCL22 protein is crucial for advancing our knowledge of immune regulation and developing targeted therapies.
